



Journal of the British Cardiovascular Society

Guidelines for Authors and Reviewers

Full instructions are available online at <http://heart.bmj.com/fora>. Articles must be submitted electronically <http://heart.bmj.com/submit>. Authors retain copyright but are required to grant *Heart* an exclusive licence to publish <http://heart.bmj.com/fora/licence.dtl>

Editorial Office

Heart, BMJ Publishing Group
BMA House, Tavistock Square
London WC1H 9JR, UK
T: +44 (0) 20 7383 6622
F: +44 (0) 20 7383 6668
E: heartjournal@bmj.com

ISSN: 1355-6037 (print)
ISSN: 1468-201X (online)

Impact factor: 5.014

Disclaimer: *Heart* is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the British Cardiovascular Society. The owners grant editorial freedom to the Editor of *Heart*. *Heart* follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

Heart is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the British Cardiovascular Society or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of *Heart* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2014 BMJ Publishing Group Ltd & British Cardiovascular Society. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.

Heart is published by BMJ Publishing Group Ltd, typeset by Techset, Chennai, India and printed in the UK on acid-free paper.

Heart (ISSN No 1355-6037) is published semi-monthly by BMJ Publishing Group and distributed in the in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: Send address changes to *Heart*, Air Business Ltd, c/o Worldnet Shipping Inc, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA

Contents

FOREWORD ii1

EXECUTIVE SUMMARY ii1

 Recommendations ii2

SECTION 1: CARDIOVASCULAR DISEASE PREVENTION ii6

 1.1 Introduction and aims ii6

 1.2 Principles of cardiovascular prevention..... ii7

 1.2.1 Established CVD ii7

 1.2.2 Risk assessment for CVD prevention in the population..... ii8

 1.2.3 Age-based approach ii8

 1.2.4 Lifetime risk for CVD..... ii8

 1.2.5 JBS3 lifetime risk approach..... ii8

 1.2.6 Summary ii10

 1.3 Risk calculator ii10

 1.3.1 Background ii10

 1.3.2 Approach ii10

 1.3.3 Lifetime risk profile ii11

 1.3.4 Intervention assumptions ii11

 1.3.5 Ongoing and unresolved issues ii13

 1.3.6 Using the JBS3 risk calculator..... ii13

 1.3.7 Conclusion ii24

 1.4 Refinement of risk models..... ii24

 1.4.1 Refining CVD risk assessment using new technologies ii24

 1.4.2 Tools to detect subclinical atherosclerosis ii24

 1.4.3 Blood markers ii25

 1.4.4 Genotype ii26

MORE CONTENTS ►



This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://heart.bmj.com/site/about/guidelines.xhtml#open>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics
www.publicationethics.org.uk



Receive regular table of contents by email.
Register using this QR code.



Heart: first published as on 1 April 2014. Downloaded from <http://heart.bmj.com/> on April 25, 2025 at Department GEZ-LTA Erasmus Hogeschool. Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1.5 Lifestyle interventions	ii26
1.5.1 Introduction.....	ii27
1.5.2 Smoking cessation: interventions and specialist services	ii27
1.5.3 Diet	ii28
1.5.4 Physical activity and exercise.....	ii30
1.5.5 Summary	ii31
1.6 Childhood and adult obesity	ii32
1.6.1 Obesity in children.....	ii32
1.6.2 Obesity in adults	ii33
1.6.3 Summary	ii33
SECTION 2: HIGH RISK OF CARDIOVASCULAR DISEASE	ii33
2.1 Lipids	ii33
2.1.1 Background	ii33
2.1.2 Treatment approaches	ii34
2.1.3 Summary	ii37
2.2 Blood pressure	ii37
2.2.1 Background	ii38
2.2.2 Diagnosis of hypertension	ii38
2.2.3 Treatment approaches	ii39
2.2.4 Summary	ii41
2.3 Established cardiovascular disease and differences in post-myocardial infarction and stroke management.....	ii41
2.3.1 Established CVD	ii42
2.3.2 Post-MI	ii42
2.3.3 Stroke	ii44
2.3.4 Summary	ii44
2.4 Peripheral arterial disease	ii45
2.4.1 Background	ii45
2.4.2 Treatment approaches	ii45
2.4.3 Summary	ii46
2.5 Type 1 and 2 diabetes mellitus.....	ii46
2.5.1 Type 1 diabetes mellitus.....	ii46
2.5.2 Type 2 diabetes mellitus.....	ii47
2.5.3 Aspirin in the prevention of CVD in patients with diabetes mellitus	ii48
2.5.4 Summary	ii49

2.6 Chronic kidney disease.....	ii49
2.6.1 Background.....	ii49
2.6.2 Treatment approaches.....	ii49
2.6.3 Summary.....	ii50
2.7 Chronic inflammatory disease.....	ii51
2.7.1 Background.....	ii51
2.7.2 Treatment approaches.....	ii51
2.7.3 Ongoing/unresolved issues.....	ii52
2.7.4 Summary.....	ii52
2.8 Chronic obstructive pulmonary disorder/sleep apnoea.....	ii52
2.8.1 Background.....	ii52
2.8.2 Treatment approaches.....	ii53
2.8.3 Ongoing/unresolved issues.....	ii53
2.8.4 Summary.....	ii53
2.9 Implementation.....	ii53
2.9.1 Introduction.....	ii53
2.9.2 Patients with established CVD.....	ii54
2.9.3 High CVD risk due to genetic elevation of CVD risk factors.....	ii54
2.9.4 Broader CVD prevention strategies.....	ii54
2.10 Research gaps and opportunities.....	ii55
2.10.1 Risk calculator.....	ii55
2.10.2 Risk refinement.....	ii55
2.10.3 Risk factors.....	ii55
2.10.4 Novel associated diseases.....	ii56
2.10.5 Clinical CVD presentations.....	ii56
2.10.6 Lifestyle changes.....	ii57
REFERENCES.....	ii57
APPENDIX 1: TECHNICAL DETAILS OF RISK CALCULATOR.....	ii65
APPENDIX 2: JBS3 CONTRIBUTORS.....	ii67